Inter‐ and intraindividual variability of long‐acting cabotegravir/rilpivirine pharmacokinetics after 1 year of continuous use

Documenti analoghi

• Physiologically‐based pharmacokinetic modelling of long‐acting injectable cabotegravir and rilpivirine in pregnancy
  di: Shakir Atoyebi, et al.
  Pubblicazione: (2024)
• Pharmacokinetics of long‐acting cabotegravir and rilpivirine in seminal plasma throughout the dosing interval
  di: N. Neverette, et al.
  Pubblicazione: (2025)
• Clinical pharmacology considerations and drug–drug interactions with long‐acting cabotegravir and rilpivirine relevant to sub‐Saharan Africa
  di: Adrian Steulet, et al.
  Pubblicazione: (2024)
• Longitudinal monitoring of cabotegravir and rilpivirine exposure from hair strand concentrations
  di: E. Rosen, et al.
  Pubblicazione: (2025)
• Minimal impact of pregnancy on rilpivirine pharmacokinetics: A POPPK approach
  Pubblicazione: (2024)